You are here

UnitedHealth Trims Drug Coverage

Lantus gets the boot for diabetes

UnitedHealth Group, the largest health insurer in the U.S., will stop covering several brand-name drugs as of next year, according to a Reuters report. In a recent bulletin, the company said it is changing reimbursement terms for long-acting insulins and will no longer cover Sanofi’s Lantus. Instead, Basaglar (Eli Lilly), a cheaper biosimilar insulin, will be covered as Tier 1.

In addition, UnitedHealth plans to move Novo Nordisk’s Levemir (insulin detemir) from Tier 1 to Tier 2.

Last month, CVS Health also announced plans to drop Lantus in favor of Lilly’s new biosimilar.

In another change, UnitedHealth said it will also exclude from coverage Amgen’s leukocyte-boosting drug Neupogen (filgrastim) in favor of the biosimilar product Zarxio (filgrastim-sndz, Sandoz).

Source: Reuters; September 22, 2016.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs